Oramed Pharmaceuticals Inc. (ORMP) Stock Price Down 2.2%
Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) traded down 2.2% during mid-day trading on Monday . The company traded as low as $7.30 and last traded at $7.45, with a volume of 53,593 shares changing hands. The stock had previously closed at $7.62.
A number of equities research analysts have recently issued reports on the company. Aegis restated a “buy” rating and issued a $18.00 price target on shares of Oramed Pharmaceuticals in a research report on Wednesday, May 18th. FBR & Co upped their price target on Oramed Pharmaceuticals from $15.00 to $20.00 and gave the company an “outperform” rating in a research report on Thursday, May 26th. Finally, Rodman & Renshaw restated a “buy” rating and issued a $25.00 price target on shares of Oramed Pharmaceuticals in a research report on Sunday, August 21st. Five investment analysts have rated the stock with a buy rating, Oramed Pharmaceuticals currently has a consensus rating of “Buy” and an average target price of $22.00.
The firm’s market capitalization is $95.70 million. The firm has a 50-day moving average of $7.91 and a 200 day moving average of $7.92.
Oramed Pharmaceuticals Inc (Oramed) is engaged in the field of oral delivery solutions for drugs and vaccines presently delivered via injection. Oramed’s flagship product, an orally ingestible insulin capsule in phase II clinical trials, is focused on the treatment of diabetes. The Company is developing orally ingestible protein oral delivery (POD) technology for the delivery of drugs presently administered by way of injection.
Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.